Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SIBIA Neurosciences (SIBI) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (355)	5/26/1999 12:39:00 PM
From: LLCF	Read Replies (1) \| Respond to of 579

I like this: "We will also be advancing compounds already identified at SIBIA that are active on nicotinic acetylcholine receptor subtypes." DAK

To: scaram(o)uche who wrote (355)	5/26/1999 4:35:00 PM
From: LLCF	Read Replies (1) \| Respond to of 579

SIBI update on Bloomberg: -Sibia hopes to eventually profit from the collaboration, but said thiswon't happen immediately. "The agreement with LLY allows us to hunt for drugs to have royalities down the road. That's where the profits come from" said Stephen Keane, a Sibia vice president. Sibia said the collaboration should produce a number of treatments for neurological and psychiatric disorders. Research targets are central nervous system disorders such as pain, schizophrenia, depression, Alzheimer's, and Parkinson's diseases. DAK